Commitments and Contingent Liabilities (Details) ₪ in Thousands, $ in Thousands |
1 Months Ended | 12 Months Ended | 84 Months Ended | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 01, 2020 |
Aug. 30, 2021
USD ($)
|
Aug. 30, 2021
ILS (₪)
|
Mar. 31, 2021
USD ($)
|
Mar. 31, 2021
ILS (₪)
|
Apr. 30, 2020
USD ($)
|
Apr. 30, 2020
ILS (₪)
|
Apr. 30, 2019 |
Dec. 31, 2017
USD ($)
|
Dec. 31, 2021
USD ($)
|
Dec. 31, 2021
ILS (₪)
|
Dec. 31, 2020
USD ($)
|
Dec. 31, 2019
USD ($)
|
Dec. 31, 2019
ILS (₪)
|
Dec. 31, 2021
USD ($)
|
Dec. 31, 2021
ILS (₪)
|
Oct. 30, 2020
USD ($)
|
Jul. 31, 2019 |
May 31, 2017
shares
|
Apr. 30, 2017
USD ($)
|
Mar. 20, 2016
USD ($)
|
Jun. 30, 2015
USD ($)
|
|
| Commitments and Contingent Liabilities (Details) [Line Items] | ||||||||||||||||||||||
| Approved budget | $ 1,778 | ₪ 5,737 | $ 5,874 | ₪ 19,444 | $ 4,287 | ₪ 15,562 | $ 781 | ₪ 2,700 | $ 4,308 | ₪ 2 | ||||||||||||
| Percentage of total fund | 50.00% | 50.00% | 30.00% | 30.00% | 30.00% | 30.00% | 85.00% | 85.00% | 30.00% | 30.00% | ||||||||||||
| Received amount | $ 313 | ₪ 1,004 | ||||||||||||||||||||
| Total research and development income | 3,741 | $ 518 | ||||||||||||||||||||
| Total approved grants | $ 7,175 | ₪ 24,782 | ||||||||||||||||||||
| Total grants received | 5,571 | ₪ 19,100 | ||||||||||||||||||||
| Total grants subject to royalties | 5,258 | |||||||||||||||||||||
| Total contingent obligation | 5,397 | |||||||||||||||||||||
| Research budget agreed | $ 1,800 | |||||||||||||||||||||
| Annual license fees | $ 10 | |||||||||||||||||||||
| Consideration received percentage | 1.00% | 1.00% | ||||||||||||||||||||
| Warrant to purchase share (in Shares) | shares | 591,382 | |||||||||||||||||||||
| Paid an initial license fee | $ 25 | |||||||||||||||||||||
| License maintenance fees | $ 250 | 250 | ||||||||||||||||||||
| Development and commercialization totaling | $ 2,350 | |||||||||||||||||||||
| Agreement amount of other liabilities | 240 | |||||||||||||||||||||
| Development and commercialization totaling | $ 4,700 | |||||||||||||||||||||
| Pay annual license fees | $ 10 | |||||||||||||||||||||
| Minimum annual license fees | $ 15 | |||||||||||||||||||||
| Maximum annual license fees subject to the terms and conditions | 25 | |||||||||||||||||||||
| Royalty payments based on achievement of milestones | $ 32,100 | |||||||||||||||||||||
| License agreement, description | (i) to pay a license issue fee of $20 and annual license fees ranging from $15 to $25 (ii) make additional payments based upon the achievement of clinical and regulatory milestones up to an aggregate of $32,100 and (iii) make tiered royalty payments, in the low single digits based on future revenue. The consolidated financial statements include liabilities with respect to this agreement in the amount of $40 and $378 as of December 31, 2021 and 2020, respectively, recorded as other liabilities. | |||||||||||||||||||||
| Research collaboration agreement, description | BiomX Israel entered into a research collaboration agreement with Boehringer Ingelheim International GmbH (“BI”) for a collaboration on biomarker discovery for IBD. Under the agreement, BiomX Israel was eligible to receive fees totaling $439 in installments of $50 within 60 days of the Effective Date, $100 upon receipt of the BI materials, $150 upon the completion of data processing and $139 upon delivery of the Final Report of observations and Results of the Project (as such terms are defined within the agreement). The Company granted BI an option to negotiate for an exclusive, worldwide, compensation-based license(s), with rights to sublicense, to use the metagenomic signature results under any patents covering such metagenomic signature results for the sole purpose of making, having made, offering for sale, selling, having sold, importing or otherwise commercializing diagnostic products, including companion diagnostics (the “Option”). The Option shall be exercisable any time until twelve months following delivery of the Final Report. BI agreed to pay to the Company fifty percent (50%) of all income that BI receives as a result of, and directly related to, the commercial exploitation of such companion diagnostic. | |||||||||||||||||||||
| Consideration received | 150 | |||||||||||||||||||||
| Total consideration received | 439 | |||||||||||||||||||||
| RondinX Ltd. [Member] | ||||||||||||||||||||||
| Commitments and Contingent Liabilities (Details) [Line Items] | ||||||||||||||||||||||
| Agreement amount of other liabilities | 175 | $ 83 | $ 175 | |||||||||||||||||||
| BiomX Israel [Member] | ||||||||||||||||||||||
| Commitments and Contingent Liabilities (Details) [Line Items] | ||||||||||||||||||||||
| Received amount | $ 625 | ₪ 2,042 | ||||||||||||||||||||
| Minimum [Member] | ||||||||||||||||||||||
| Commitments and Contingent Liabilities (Details) [Line Items] | ||||||||||||||||||||||
| Royalties rate | 3.00% | 3.00% | ||||||||||||||||||||
| Maximum [Member] | ||||||||||||||||||||||
| Commitments and Contingent Liabilities (Details) [Line Items] | ||||||||||||||||||||||
| Royalties rate | 3.50% | 3.50% | ||||||||||||||||||||